← Back to Screener
Sera Prognostics, Inc. Class A Common Stock (SERA)
Price$2.29
Favorite Metrics
Price vs S&P 500 (26W)-33.58%
Price vs S&P 500 (4W)15.85%
Market Capitalization$90.03M
All Metrics
Book Value / Share (Quarterly)$1.94
P/TBV (Annual)1.53x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-33.06%
Cash Flow / Share (Quarterly)$-0.68
Price vs S&P 500 (YTD)-26.17%
Gross Margin (TTM)-102.47%
Net Profit Margin (TTM)-39417.28%
EPS (TTM)$-0.67
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-0.67
Revenue Growth (5Y)21.98%
EPS (Annual)$-0.67
ROI (Annual)-42.34%
Gross Margin (Annual)-102.47%
Net Profit Margin (5Y Avg)-30822.98%
Cash / Share (Quarterly)$1.01
Revenue Growth QoQ (YoY)-58.33%
ROA (Last FY)-31.32%
Revenue Growth TTM (YoY)5.19%
EBITD / Share (TTM)$-0.75
ROE (5Y Avg)-46.55%
Operating Margin (TTM)-45066.67%
Cash Flow / Share (Annual)$-0.68
P/B Ratio1.19x
P/B Ratio (Quarterly)1.51x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1062.83x
Net Interest Coverage (TTM)-57.35x
ROA (TTM)-29.02%
EPS Incl Extra (Annual)$-0.67
Current Ratio (Annual)1.69x
Quick Ratio (Quarterly)1.62x
3-Month Avg Trading Volume0.06M
52-Week Price Return-31.34%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.91
P/S Ratio (Annual)1111.49x
Asset Turnover (Annual)0.00x
52-Week High$4.09
Operating Margin (5Y Avg)-33100.58%
EPS Excl Extra (Annual)$-0.67
CapEx CAGR (5Y)37.08%
26-Week Price Return-24.84%
Quick Ratio (Annual)1.62x
13-Week Price Return-35.03%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.69x
Enterprise Value$86.089
Revenue / Share Growth (5Y)11.20%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-39417.28%
Cash / Share (Annual)$1.01
3-Month Return Std Dev76.61%
Gross Margin (5Y Avg)2.91%
Net Income / Employee (TTM)$-1
ROE (Last FY)-42.34%
Net Interest Coverage (Annual)-16.01x
EPS Basic Excl Extra (Annual)$-0.67
Receivables Turnover (TTM)3.52x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.67
Receivables Turnover (Annual)3.52x
ROI (TTM)-37.48%
P/S Ratio (TTM)1111.49x
Pretax Margin (5Y Avg)-30822.98%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.91
Price vs S&P 500 (52W)-66.44%
Year-to-Date Return-22.03%
5-Day Price Return7.98%
EPS Normalized (Annual)$-0.67
ROA (5Y Avg)-35.29%
Net Profit Margin (Annual)-39417.28%
Month-to-Date Return13.30%
Cash Flow / Share (TTM)$-1.20
EBITD / Share (Annual)$-0.75
Operating Margin (Annual)-45066.67%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-46.30%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.67
P/TBV (Quarterly)1.53x
P/B Ratio (Annual)1.51x
Pretax Margin (TTM)-39417.28%
Book Value / Share (Annual)$1.94
Price vs S&P 500 (13W)-37.89%
Beta1.01x
Revenue / Share (TTM)$0.00
ROE (TTM)-37.50%
52-Week Low$1.37
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.33
4.33
4.33
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
SERASera Prognostics, Inc. Class A Common Stock | — | 5.19% | -45066.67% | -37.50% | $2.29 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $207.74 |
LHLabcorp Holdings Inc. | 25.31x | 7.25% | 9.92% | 10.28% | $269.19 |
DGXQuest Diagnostics Inc. | 21.75x | 11.78% | 14.10% | 13.88% | $196.31 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $91.07 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $57.85 |
VCYTVeracyte, Inc. | 39.66x | 16.01% | 11.17% | 5.33% | $33.45 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $51.20 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $21.29 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.44 |
About
Sera Prognostics develops blood-based diagnostic tests that predict individualized maternal health risks, including premature birth, preeclampsia, gestational diabetes, and stillbirth. Using proprietary proteomics and bioinformatics technology, the company commercializes biomarker tests and predictive analytics products to improve maternal and neonatal health outcomes.